Optimized Oral Formulation Demonstrates Favorable Oral Bioavailability Together with Robust Brain and Liver Distribution ...

Halozyme Therapeutics (NASDAQ:HALO) has entered into a global collaboration and license agreement with Incyte (NASDAQ:INCY) ...

A harmonized control strategy can ensure that polysorbate degradation does not lower biologic quality or efficacy.

Oncotelic Therapeutics, Inc. (OTCQB: OTLC) and Sapu Nano today announced the publication of a comprehensive peer-reviewed study in Biomedicines describing the preclinical translational package ...

What it takes to produce complex OSD drug products from the earliest stages of development to rapid, low-risk tech transfer ...

FDA feedback provides detailed manufacturing and formulation requirements for continued late-stage development of NEO212CALABASAS, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings ...

Review Article Now Published in the British Journal of Clinical Pharmacology Finds Widely Sold Non-Prescription CBD Products ...

Learn how Piramal Pharma is expanding India's global reputation through pharmaceutical manufacturing, development expertise, ...

New Preclinical Data Demonstrate Favorable Oral Bioavailability, Robust Brain Penetration and Liver Exposure with ...

Agreement provides Incyte the rights to develop and commercialize ENHANZE® with its mutCALR development program and an option to nominate up to two additional targets ...

The global pharmaceutical packaging market is undergoing a significant transformation, driven by an escalating demand for secure, chemically inert, and high-precision containment solutions. Among the ...

FIIs increased their stakes in IOL Chemicals and Granules India during Q1FY27. Here's why these pharma companies are in focus ...